# Summary Report: AMR Surveillance in Kurdistan Region, Iraq

## Twelve-Year Analysis (2013-2025)

**Institution**: Zakho General Emergency Hospital  
**Department**: Microbiology Laboratory  
**Analysis Date**: December 2025

---

## Executive Summary

This report presents findings from a retrospective analysis of antimicrobial resistance (AMR) patterns at Zakho General Emergency Hospital over a 12-year period (2013-2025). The dataset comprises approximately 1,200+ bacterial isolates from clinical specimens, making it one of the most comprehensive AMR surveillance studies from the Kurdistan Region of Iraq.

### Key Findings

*[To be completed after data analysis]*

1. **Most Common Pathogens**: 
   - *Escherichia coli* (XX%)
   - *Klebsiella* spp. (XX%)
   - *Staphylococcus* spp. (XX%)

2. **Critical Resistance Patterns**:
   - Carbapenem resistance: XX%
   - Third-generation cephalosporin resistance: XX%
   - Fluoroquinolone resistance: XX%

3. **MDR Prevalence**: XX% of isolates were classified as multi-drug resistant

4. **Temporal Trends**: [Describe trends - increasing/decreasing/stable]

---

## 1. Introduction

### 1.1 Background
Antimicrobial resistance (AMR) is a critical global health threat. The Kurdistan Region of Iraq is underrepresented in global AMR surveillance databases, creating a significant knowledge gap for regional healthcare planning.

### 1.2 Objectives
1. Describe the distribution of bacterial pathogens in clinical specimens
2. Calculate resistance rates for key antibiotics
3. Analyze temporal trends in resistance patterns
4. Estimate MDR prevalence
5. Compare findings with regional and global data

---

## 2. Methods

### 2.1 Study Design
- Retrospective laboratory-based surveillance
- Period: November 2013 – November 2025

### 2.2 Setting
- Zakho General Emergency Hospital
- Microbiology Laboratory

### 2.3 Data Sources
- Laboratory logbooks (2013-2022)
- KoBoToolbox digital records (2024-2025)

### 2.4 Laboratory Methods
- Culture and identification: Standard microbiological techniques
- Susceptibility testing: Kirby-Bauer disk diffusion (CLSI guidelines)

---

## 3. Results

### 3.1 Dataset Overview

| Parameter | Value |
|-----------|-------|
| Total isolates | *[n]* |
| Study period | 2013-2025 |
| Sample types | Urine, Sputum, Swabs |

### 3.2 Organism Distribution

*[Insert figure: organism_distribution.png]*

| Organism | n | % |
|----------|---|---|
| *Escherichia coli* | - | - |
| *Klebsiella* spp. | - | - |
| *Staphylococcus aureus* | - | - |
| *Staphylococcus* spp. | - | - |
| *Streptococcus* spp. | - | - |
| Other | - | - |

### 3.3 Antimicrobial Resistance Rates

*[Insert figure: resistance_heatmap.png]*

#### 3.3.1 Overall Resistance Rates

| Antibiotic | Resistance Rate (%) | 95% CI | n tested |
|------------|---------------------|--------|----------|
| Ampicillin | - | - | - |
| Amoxicillin-Clavulanate | - | - | - |
| Ceftriaxone | - | - | - |
| Ciprofloxacin | - | - | - |
| Gentamicin | - | - | - |
| Amikacin | - | - | - |
| Meropenem | - | - | - |
| Vancomycin | - | - | - |

#### 3.3.2 Resistance Rates by Organism

##### *Escherichia coli*
| Antibiotic | Resistance (%) |
|------------|----------------|
| Ampicillin | - |
| Ciprofloxacin | - |
| Ceftriaxone | - |
| Amikacin | - |

##### *Klebsiella* spp.
| Antibiotic | Resistance (%) |
|------------|----------------|
| Ampicillin | - |
| Ciprofloxacin | - |
| Ceftriaxone | - |
| Meropenem | - |

### 3.4 Temporal Trends

*[Insert figure: resistance_trends.png]*

#### Key Observations:
- [Antibiotic 1]: [Trend description]
- [Antibiotic 2]: [Trend description]
- [Antibiotic 3]: [Trend description]

### 3.5 Multi-Drug Resistance (MDR)

*[Insert figure: mdr_trends.png]*

| Category | n | % |
|----------|---|---|
| Susceptible | - | - |
| Resistant (1-2 classes) | - | - |
| MDR (≥3 classes) | - | - |

---

## 4. Discussion

### 4.1 Comparison with Regional/Global Data

| Organism | Antibiotic | Local (%) | EMRO Median (%) | Global Median (%) |
|----------|------------|-----------|-----------------|-------------------|
| *E. coli* | Ciprofloxacin | - | 55 | 45 |
| *E. coli* | Ceftriaxone | - | 40 | 30 |
| *Klebsiella* | Meropenem | - | 20 | 10 |

### 4.2 Clinical Implications

1. **Empiric Therapy Recommendations**:
   - [Recommendations based on findings]

2. **Antibiotics to Avoid**:
   - [List of antibiotics with high resistance]

3. **Infection Prevention**:
   - [Key recommendations]

### 4.3 Limitations

1. Single-center study
2. Retrospective design
3. Phenotypic identification methods
4. Variable antibiotic testing panels

---

## 5. Conclusions

[Summary of main conclusions]

---

## 6. Recommendations

### For Clinical Practice
1. [Recommendation 1]
2. [Recommendation 2]

### For Hospital Policy
1. [Policy recommendation 1]
2. [Policy recommendation 2]

### For Future Research
1. [Research priority 1]
2. [Research priority 2]

---

## References

1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. M100.

2. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022.

3. Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria. Clin Microbiol Infect. 2012;18(3):268-281.

---

## Appendices

### Appendix A: Antibiotic Abbreviations
See `docs/data_dictionary.md`

### Appendix B: Statistical Methods
See `docs/methodology.md`

### Appendix C: Data Availability
Raw and processed data available at: [GitHub Repository URL]

---

*Report generated: December 2025*  
*Author: [Your Name]*  
*Contact: [Email]*
